Yeo C J, Cameron J L
Johns Hopkins Hospital, Baltimore, MD 21287-4606, USA.
Langenbecks Arch Surg. 1998 Apr;383(2):129-33. doi: 10.1007/s004230050104.
The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4-8 months post-diagnosis.
A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.
对于大多数患者及其家属而言，胰腺腺癌的诊断仍然是一个毁灭性的生活事件。许多患有这种相对常见恶性肿瘤的患者在疾病阶段就诊时，已不适用于针对癌症的切除治疗，而是通过非手术姑息措施进行治疗，诊断后的中位生存期为4至8个月。
少数患者的疾病局限于胰腺和壶腹周围区域，是切除治疗的候选对象。这些患者的预后由几个因素决定：临床病理分期、肿瘤生物学和分子遗传学、围手术期因素以及术后辅助治疗的使用。
